BURLINGTON, N.C., May 13, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit for ages 2-17. The authorization expands the use of Pixel by Labcorp to children and adolescents 2 years of age and older when purchased by a parent or guardian.
COVID-19 News
View our latest news about advancements in health science, COVID-19, and more.
Jul 1 2021
Labcorp Extends COVID-19 Genomic Sequencing Work With The CDC
BURLINGTON, N.C., June 30, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the extension of its work with the U.S. Centers for Disease Control and Prevention (CDC) to help identify and monitor variants of SARS-CoV-2, the virus that causes COVID-19.
Read more »
Jun 22 2021
Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance
Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples. This sequencing is being performed as part of a U.S. Centers for Disease Control and Prevention (CDC) effort to identify and track the spread of SARS-CoV-2 variants throughout the country.
Jun 16 2021
NCDHHS Expands Home Testing Program to All Eligible North Carolinians
The North Carolina Department of Health and Human Services today announced the state is expanding availability of its at-home COVID-19 test collection. Any North Carolina resident may receive a Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit that is shipped overnight directly to their homes at no cost. Tests can be used on people age 2 and up.
May 25 2021
Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection
BURLINGTON, N.C.--(BUSINESS WIRE)--May 24, 2021-- Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.
May 11 2021
Labcorp and the U.S. Department of Health and Human Services Join Forces to Raise Awareness of COVID-19 Treatments
BURLINGTON, N.C., May 11, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, is working with the U.S. Department of Health and Human Services (HHS) to raise awareness of potentially lifesaving monoclonal antibody COVID-19 therapies.
Apr 20 2021
Labcorp Launches COVID-19 Test Kits For Small Businesses to Support Return to Work and Life Safely
BURLINGTON, N.C. — Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of the Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit for small businesses, an initiative aimed at providing fast, convenient, and reliable testing for companies with as many as 120 employees. Labcorp Employer Services currently provides COVID-19 testing and vaccination services for larger organizations and communities.
Mar 26 2021
NCDHHS Pilots Home Testing Program with Labcorp to Increase Access to Testing
RALEIGH — While vaccine supplies are limited, it is important North Carolinians continue practicing the 3Ws and get tested for COVID-19 if they have symptoms or have been in close contact to someone with COVID-19.
Feb 24 2021
Walgreens to Make Pixel by Labcorp™ COVID-19 PCR Test Home Collection Kit Available Over-The-Counter at Stores Nationwide
Kit to be available for purchase at Walgreens without a prescription and will allow for greater access to testing, helping reduce the spread of COVID-19 and improve the health of communities
Feb 24 2021
Natick, Massachusetts Mass Vaccination Site | Opening Remarks | Bill Haas, senior vice president, Northeast Division, Labcorp
Thank you for joining us today at our mass vaccination site here at the Natick Mall. I’m Bill Haas, senior vice president of the northeast division at Labcorp. We’re thrilled to be working across the commonwealth to make it easier for people to get tested and vaccinated, as we all work together to slow the spread of COVID-19.
Feb 19 2021
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19
Labcorp Using PacBio’s HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.
Feb 17 2021
Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection
Antigen Test Is the Latest Offering by Labcorp to Fight COVID-19 at Every Stage, from Diagnostic Testing to Clinical Trials and Vaccination Services
Jan 8 2021
Media Statement: Tracking Mutations of the SARS CoV2
We have been regularly tracking mutations of the virus throughout the pandemic to determine the impact it would have on our PCR sensitivity. To date, we have not seen any impact. Our current capacity for PCR tests is 270k and we continue to operate with a 1-2 day turnaround. The only way to identify the strain is by sequencing, and we have research support underway that includes sequencing of the virus.
Labcorp's COVID-19 PCR Testing
1-2 Days
Average Time to Result from Specimen Pickup
45M
Molecular tests performed
275K
Molecular test capacity per day**
5.5M
Antibody tests performed
300K
Antibody test capacity per day**
$0
Tests Offered with No Upfront Costs*
Stats updated as of July 31, 2021. COVID-19 volumes are U.S. only. Future COVID-19 test volumes will be updated quarterly after the release of Labcorp’s quarterly earnings results.
*A $10 non-refundable physician fee is charged for the IgG antibody test if it is requested through Labcorp.com
**Capacity numbers are subject to sufficient equipment and supplies
Tracking COVID-19 Variants
We have been regularly tracking variants of the virus throughout the pandemic. The sensitivity of our PCR test is not impacted by these variants.
Labcorp PCR Test Performance Confirmed
Variant B.1.1.7 (Alpha, Common name: U.K. Variant)
Variant B.1.351 (Beta Common name: South Africa Variant)
Variant P.1 (Gamma, Common name: Brazil Variant)
Variant B.1.526 (Iota, Common name: New York Variant)
Variant B.1.617.2 (Delta, Common name: India Variant)
Variant C.37 (Lambda, Common name: Peru Variant)
Labcorp has been working with the Centers for Disease Control and Prevention (CDC) to provide sequencing of samples of SARS-CoV-2, the virus that causes COVID-19.
For more information visit US COVID-19 Cases Caused by Variants on the CDC website.
Data covers the U.S. including the District of Columbia and Puerto Rico.
Total number of samples sequenced: 70,000 (as of July 2, 2021)
Media Information
For Media Inquiries
Christopher Allman-Bradshaw
or Rachael Valdez
Phone: 336-436-8263
Email: [email protected]
Digital Assets
If you use any of this imagery or footage, please use Photo/Video credit: Labcorp
Download B-roll
Download Images